Camargo

JULY 27, 2021

Viruses and bacteria can be first modified to prevent them from causing infectious diseases and then implemented into human tissues as therapeutic gene vectors. While most gene therapy clinical studies are ongoing, a number of products are in advanced clinical development, and several are approved by FDA.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Pharmaceutical Technology

MARCH 24, 2023

TB is caused by the bacillus Mycobacterium tuberculosis and is transmitted when infected individuals expel bacteria into the air (e.g., Helen McShane, PhD, a professor of vaccinology at the University of Oxford, says, “Twenty-three years ago, there were no new TB vaccines being tested in clinical trials. by coughing).

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

The Pharma Data

JUNE 18, 2021

We are thrilled with this approval as it furthers our mission to expand protection against disease-causing bacteria serotypes to help prevent potentially serious respiratory infections like pneumococcal pneumonia throughout the year.”. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved based on immune responses.

Vaccination 52

Vaccination Vaccine FDA Approval Containment 52

pharmaphorum

JULY 14, 2021

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

XTalks

NOVEMBER 12, 2024

Pneumonia is a lung infection that can be caused by viruses, bacteria or fungi and can result in millions of hospitalizations and deaths annually. For example, recent clinical trials and regulatory approvals for RSV vaccines are notable milestones that indicate advancements in preventing viral pneumonia in both children and elderly adults.

Bacteria 110

Bacteria Life Science Vaccination Vaccine 110

XTalks

AUGUST 18, 2021

Of important note is the aberrant immune response that occurs in patients with COVID-19, including the intensive release of cytokines (cytokine storm), which can make a patient infected with SARS-CoV2 more susceptible to contracting a bacterial respiratory infection.

Development 105

Development Bacteria Drugs Vaccination 105

XTalks

DECEMBER 17, 2021

And in healthcare and health research, trends towards increased digitization continued, including remote monitoring in clinical trials, use of wearable technologies and AI-based approaches to data collection, management and analysis. The year 2021 was all about continuing innovations in the life sciences.

Life Science 98

Life Science Vaccination Vaccine Trials 98

pharmaphorum

DECEMBER 15, 2020

million (around $56 million) in a Series B funding round to take its novel group B streptococcus (GBS) vaccine into mid-stage clinical trials. Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through phase 2 clinical trials, as well as manufacturing and regulatory preparation for phase 3.

Bacteria 52

Bacteria Vaccination Vaccine Immune Response 52